Roger D. Weiss, MD | Professor of Psychiatry, Harvard Medical School; Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA
Buprenorphine has unique pharmacological properties that make it a useful treatment for opioid use disorder. Unlike other treatments, buprenorphine is the first medication to treat opioid dependency that is permitted to be prescribed or dispensed in physician offices. Under the Drug Addiction Treatment Act of 2000 (DATA 2000), U.S physicians can prescribe buprenorphine for opioid use disorder in several settings including correctional facilities, community hospitals, medical offices, and health departments.
Although counseling is a required part of office-based buprenorphine treatment of opioid use disorders; the nature of what constitutes appropriate counseling is unclear and sometimes controversial.
This webinar will review the literature on the role, nature, and intensity of behavioral interventions in office-based buprenorphine treatment for patients with opioid use disorders. Participants will understand the clinician’s responsibilities in office-based buprenorphine treatment and will learn how to best tailor their practice to meet the needs of their patients.
- Explain how research design can influence the perceived effect of counseling in the treatment of opioid use disorder
- Describe the interplay of buprenorphine, medical management, and counseling in the treatment of opioid use disorder
Accreditation and Designation
The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Psychiatric Association designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.